BioXcel Therapeutics (BTAI) Misses Q2 EPS by 16c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. DASH
9. MA
10. FND

Go back to BioXcel Therapeutics (BTAI) Misses Q2 EPS by 16c

BioXcel Therapeutics (BTAI) to prioritize high-potential agitation market opportunities for BXCL501 in bipolar disorders, schizophrenia, and Alzheimer’s disease

August 14, 2023 7:01 AM EDT

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced its financial results for the second quarter ended June 30, 2023, and a strategic reprioritization to strengthen its focus and significantly reduce operating expenses.

Strategic Reprioritization and Clinical Development InitiativesFollowing a comprehensive review of the business, the Company has determined to focus on high-potential agitation-market opportunities using its innovative, AI-based clinical drug development platforms. The Company intends to reduce more than 50% of its cash burn to approximately $80 million... More

BioXcel Therapeutics (BTAI) Halted, News Pending

August 14, 2023 6:55 AM EDT

BioXcel Therapeutics (NASDAQ: BTAI) Halted, News Pending

... More